HC Wainwright & Co. Initiates Coverage On Parabilis Medicines with Buy Rating, Announces Price Target of $40
Benzinga Newsdesk 1 week ago
Analyst RatingsNewsInitiationPrice Target
HC Wainwright & Co. initiates coverage on Parabilis Medicines (NASDAQ:PBLS) with a Buy rating and announces Price Target of $40.
HC Wainwright & Co. initiates coverage on Parabilis Medicines (NASDAQ:PBLS) with a Buy rating and announces Price Target of $40.